Merck KGaA shores up Rebif defenses to fend off new MS rivals | PharmaBoardroom
written on 06.03.2014
Tags:
,

Merck KGaA shores up Rebif defenses to fend off new MS rivals

TAGS: ,

Merck KGaA's multiple sclerosis treatment Rebif is holding its own. Considering that the German drugmaker's flagship product faces some formidable new competitors–including Biogen Idec's brand-new powerhouse, Tecfidera–that's not too shabby.

Latest Report